Occudo Quantitative Strategies’s Zevra Therapeutics ZVRA Stock Holding History

Occudo Quantitative Strategies’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,138	Closed	-$125K	–	910
2025 Q2	$125K	Buy	+14,138	New	+$115K	0.01%	562
2023 Q4	–	Sell	-22,615	Closed	-$109K	–	1259
2023 Q3	$109K	Buy	22,615 +6,404	+40%	+$32K	0.01%	871
2023 Q2	$82.7K	Sell	16,211 -1,761	-10%	-$9.49K	0.01%	942
2023 Q1	$98.8K	Buy	17,972 +4,457	+33%	+$23.6K	0.01%	821
2022 Q4	$62K	Sell	13,515 -13,797	-51%	-$70.1K	0.01%	875
2022 Q3	$170K	Sell	27,312 -15,036	-36%	-$85.2K	0.01%	984
2022 Q2	$189K	Sell	42,348 -16,638	-28%	-$75.8K	0.02%	923
2022 Q1	$297K	Buy	+58,986	New	+$375K	0.02%	825

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Occudo Quantitative Strategies's ZVRA Position: Q3 2025 in Review

Occudo Quantitative Strategies sold out of Zevra Therapeutics (ZVRA) in Q3 2025, closing a stake of 14,138 shares — an estimated $125K sold.

Occudo Quantitative Strategies first reported a position in ZVRA in Q1 2022 and held it in 8 quarters. The position peaked at $297K in Q1 2022. 166 funds tracked by Wall St. Rank hold ZVRA as of Q3 2025.

Occudo Quantitative Strategies reported no remaining Zevra Therapeutics position as of Q3 2025 after selling out during the quarter.
Occudo Quantitative Strategies sold 14,138 Zevra Therapeutics shares in Q3 2025, an estimated $125K.
Occudo Quantitative Strategies first reported a position in Zevra Therapeutics in Q1 2022 and held it in 8 quarters.
Occudo Quantitative Strategies's Zevra Therapeutics position peaked at $297K in Q1 2022.
166 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.